Alpha-ketoglutarate
A central metabolic intermediate with mouse healthspan findings and unfinished human geroscience questions.
Status database
This linkable reference asset pulls from the typed fact-sheet library so each row points back to a full source-backed page.
A central metabolic intermediate with mouse healthspan findings and unfinished human geroscience questions.
An experimental synthetic peptide popular online despite very limited reliable human evidence.
A melanocortin-receptor peptide approved for a narrowly defined sexual-desire disorder.
An investigational long-acting amylin analog studied alone and with semaglutide for obesity and type 2 diabetes.
An unapproved growth hormone-releasing hormone analog with limited human data.
A well-studied performance supplement with credible muscle evidence and a less certain cognitive-aging frontier.
An experimental senolytic pairing that combines a serious cancer medicine with a flavonoid.
A mitochondria-targeting peptide with an accelerated FDA approval for a narrow Barth syndrome indication.
An FDA-approved diabetes peptide whose promising Phase 2 Parkinson signal failed in a larger Phase 3 trial.
A plant flavonoid with striking mouse senolytic findings but no proven human longevity or frailty benefit.
A copper-binding tripeptide used in cosmetic research, with mostly laboratory and animal wound-healing evidence.
An unapproved ghrelin-receptor agonist that raises growth hormone and appetite without proven muscle-building outcomes.
A mitochondrial-derived peptide studied for cell survival, neuroprotection, metabolism, and aging mostly in preclinical work.
An unapproved growth hormone secretagogue with limited clinical evidence and FDA-identified concerns.
Compounds that raise circulating ketones reliably but have not established cognitive or healthy-aging benefit.
A reproductive signaling peptide studied in fertility, hormone release, and brain responses.
A minimally absorbed peptide medicine approved for several constipation disorders in defined adult and pediatric populations.
An established GLP-1 medicine approved for specific diabetes and weight-management uses.
A discontinued U.S. GLP-1 product with established diabetes evidence and an encouraging but unconfirmed Parkinson trial.
A foundational diabetes medicine being studied in geroscience, without an approved anti-aging use.
A mitochondrial-derived peptide with intriguing metabolic and exercise biology but no proven human therapy.
A central cellular coenzyme with legitimate biology but little clinical-outcomes evidence for wellness infusions.
An NAD+ precursor with small human trials and unresolved real-world clinical value.
An NAD+ precursor that reliably changes biomarkers but has not shown a consistent anti-aging or cognitive benefit.
A natural peptide hormone with approved obstetric products and unproven intranasal cognitive or social uses.
An investigational glucagon/GLP-1 dual agonist in mid-stage research for MASH, liver fat, and obesity.
An FDA-approved gut-signaling peptide for chronic idiopathic constipation and IBS with constipation in adults.
An FDA-approved amylin analog for selected insulin-treated diabetes patients, with unapproved weight-management research.
An investigational triple-receptor agonist in Phase 3 clinical trials.
An investigational hepcidin-mimetic peptide under FDA priority review for polycythemia vera.
An unapproved synthetic heptapeptide studied for anxiety, with a thin and uncertain human evidence base.
A GLP-1 medicine with FDA-approved products for type 2 diabetes and chronic weight management.
An unapproved neuroactive heptapeptide with old, small human studies and substantial evidence gaps.
A growth hormone-releasing hormone analog whose former FDA-approved product was discontinued.
An MC4-receptor peptide medicine approved for obesity caused by specific rare genetic conditions.
An FDA-approved immunosuppressant with serious risks and unproven longevity use in healthy people.
A food-derived polyamine linked to autophagy biology, with a negative phase 2 cognitive primary outcome.
An investigational glucagon/GLP-1 dual agonist in Phase 3 research for obesity and metabolic liver disease.
A common nutrient-related molecule whose animal longevity story is challenged by newer human aging data.
An FDA-approved GLP-2 analog that improves intestinal absorption in short bowel syndrome dependent on parenteral support.
A growth hormone-releasing factor analog approved for a narrow HIV-related indication.
An immune-modulating peptide used in some countries but not FDA approved for any U.S. indication.
A naturally occurring peptide studied in tissue repair; marketed fragments are not FDA approved.
A dual GIP/GLP-1 receptor agonist approved for specific metabolic and sleep-apnea uses.
An FDA-approved synthetic peptide analog for Rett syndrome with modest trial benefits and frequent gastrointestinal adverse effects.
A mitophagy-related metabolite with human biomarker and muscle-endurance signals but no approved disease use.
A C-type natriuretic peptide analog approved to increase growth in children with achondroplasia.
A cone-snail-inspired peptide medicine approved for severe chronic pain under specialist care.